Please use this identifier to cite or link to this item:
|Title:||Cost-effectiveness of Pharmacogenomics in Clinical Practice: A Case Study of Thyopurine Methyltransferase Genotyping in Acute Lymphoblastic Leukaemia in Europe|
|Authors:||VAN DER AKKERVAN MARLE Elske; GURWITZ David; DETMAR Symone; ENZING Christien; HOPKINS Michael; GUTIERREZ DE MESA Emma; IBARRETA RUIZ DOLORES|
|Citation:||PHARMACOGENOMICS vol. 7 no. 5 p. 783-792|
|Publisher:||FUTURE MEDICINE LTD|
|Type:||Articles in periodicals and books|
|Abstract:||Only a few studies have addressed the cost-effectiveness of pharmacogenetics interventions in healthcare. Lack of health economics data on aspects of pharmacogenetics is perceived as one of the barriers hindering its implementation for improving drug safety. Thus, a recent Institute for Prospective Technological Studies (IPTS) study entitled "Pharmacogenetics and pharmacogenomics: State-of-the-art and potential socio-economic impact in the EU" included an explorative cost-effectiveness review for a pharmacogenetic treatment strategy compared with traditional medical practice. The selected case study examined the cost-effectiveness of thiopurine methyltransferase (TMPT) genotyping prior to thiopurine treatment in children with acute lymphoblastic leukemia (ALL). Information for the cost-effectiveness model parameters was collected from literature surveys and interviews with experts from four European countries (Germany, Ireland, the Netherlands and the United Kingdom). The model has established that TPMT testing in ALL patients has a favorable cost-effectiveness ratio. This conclusion was based on parameters collected for TPMT genotyping costs, estimates for frequency of TMPT deficiency, rates of thiopurine-mediated myelosuppression in TPMT-deficient individuals, and myelosuppression-related hospitalization costs in each of the four countries studied. The mean calculated cost per life-year gained by TPMT genotyping in ALL patients in the four study countries was EUR 2100 (or EUR 4800 after 3% discount) based on genotyping costs of EUR 150 per patient. Cost per life-year gained is expected to further improve following the introduction of wider use of TMPT genotyping and the availability of lower cost genotyping methods. Our analysis indicates that TPMT genotyping should be seriously considered as an integral part of healthcare prior to initiation of therapy with thiopurine drugs.|
|JRC Directorate:||Growth and Innovation|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.